Health & Wellness
Anti-Amyloid Alzheimer’s Drugs Face New Doubts: Cochrane Review Finds ‘Trivial’ Effects
A bombshell Cochrane review questions the effectiveness of anti-amyloid Alzheimer’s drugs like Leqembi and Kisunla, calling their benefits “absent or trivial” despite FDA approvals. Cochrane Analysis: Little to No Clinical Benefit The nonprofit Cochrane compiled data from 17 placebo-controlled studies on seven amyloid-beta-targeting monoclonal antibodies, involving over 20,000 people with mild cognitive impairment or mild Alzheimer’s dementia.